Mersana Therapeutics Company Leadership

MRSN Stock  USD 0.64  0.05  8.47%   
Mersana Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Mersana Therapeutics suggests that virtually all insiders are panicking. Mersana Therapeutics employs about 123 people. The company is managed by 14 executives with a total tenure of roughly 12 years, averaging almost 0.0 years of service per executive, having 8.79 employees per reported executive.
Ashish Mandelia  President
Vice President Controller
Brian DeSchuytner  President
Senior Vice President - Finance and Product Strategy

Mersana Therapeutics' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2025-01-16Timothy B LowingerDisposed 8048 @ 0.58View
2025-01-14Timothy B LowingerDisposed 3483 @ 0.66View
2024-10-28Mohan BalaDisposed 1884 @ 1.9View
2024-10-03Alejandra CarvajalDisposed 5598 @ 1.96View
2024-10-02Brian DeschuytnerDisposed 8089 @ 2View
2024-09-12Martin H Jr. HuberDisposed 50423 @ 1.76View
Monitoring Mersana Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.

Mersana Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.263) % which means that it has lost $0.263 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1333) %, meaning that it created substantial loss on money invested by shareholders. Mersana Therapeutics' management efficiency ratios could be used to measure how well Mersana Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 31st of January 2025, Return On Tangible Assets is likely to drop to -0.92. In addition to that, Return On Capital Employed is likely to drop to -0.99. At this time, Mersana Therapeutics' Other Current Assets are very stable compared to the past year. As of the 31st of January 2025, Fixed Asset Turnover is likely to grow to 5.34, while Total Assets are likely to drop about 180.4 M.
As of the 31st of January 2025, Common Stock Shares Outstanding is likely to grow to about 140.2 M, though Net Loss is likely to grow to (174.6 M).

Mersana Therapeutics Workforce Comparison

Mersana Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 4,189. Mersana Therapeutics holds roughly 123 in number of employees claiming about 2.94% of equities under Health Care industry.
The company has Profit Margin (PM) of (2.14) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.96) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.96.

Mersana Therapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mersana Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mersana Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Mersana Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Mersana Therapeutics Notable Stakeholders

A Mersana Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Mersana Therapeutics often face trade-offs trying to please all of them. Mersana Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Mersana Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Martin MDCEO PresidentProfile
MD HuberCEO PresidentProfile
Ashish MandeliaVice President ControllerProfile
Brian DeSchuytnerSenior Vice President - Finance and Product StrategyProfile
Alejandra JDSecretary SVPProfile
Chuck MillerSenior AffairsProfile
Carla PoulsonChief OfficerProfile
Marc DamelinOncology, BiologyProfile
Jason FredetteSenior CommunicationsProfile
Mohan BalaSenior OfficerProfile
Tushar MisraSenior OfficerProfile
Timothy LowingerChief Scientific OfficerProfile
Anna MBACEO PresProfile
Mikhail PapisovCoFounderProfile

About Mersana Therapeutics Management Performance

The success or failure of an entity such as Mersana Therapeutics often depends on how effective the management is. Mersana Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Mersana management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Mersana management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.87)(0.92)
Return On Capital Employed(0.95)(0.99)
Return On Assets(0.87)(0.92)
Return On Equity(5.35)(5.08)

Mersana Therapeutics Workforce Analysis

Traditionally, organizations such as Mersana Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Mersana Therapeutics within its industry.

Mersana Therapeutics Manpower Efficiency

Return on Mersana Therapeutics Manpower

Revenue Per Employee299.6K
Revenue Per Executive2.6M
Net Loss Per Employee1.4M
Net Loss Per Executive12.3M
Working Capital Per Employee1.2M
Working Capital Per Executive10.7M
When determining whether Mersana Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mersana Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mersana Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mersana Therapeutics Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.60)
Revenue Per Share
0.286
Quarterly Revenue Growth
0.637
Return On Assets
(0.26)
Return On Equity
(2.13)
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.